Miconazole - Tibotec

Drug Profile

Miconazole - Tibotec

Alternative Names: Tibozole

Latest Information Update: 09 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen Therapeutics; RHEI Pharmaceuticals
  • Class Antifungals; Imidazoles; Small molecules
  • Mechanism of Action Cell membrane modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Oropharyngeal candidiasis

Most Recent Events

  • 09 Apr 2015 Miconazole is approved and is in phase-III development for Oropharyngeal candidiasis in Ukraine, Africa and China, respectively
  • 27 Aug 2012 Phase III development is ongoing in China
  • 09 Dec 2008 Phase-III clinical trials in Oropharyngeal candidiasis in China (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top